A serial entrepreneur and a promising drug emerge from failed companies to pursue subsets of obesity patients, with or ...

Novo Nordisk shares were 9.5% higher after the pharmaceutical giant said an experimental weight-loss shot showed patients ...

Novo Nordisk announced positive trial results for its next-generation obesity drug, leading to a 7.13% surge in its share ...

Major heart health risk factors like obesity, diabetes and high blood pressure remain on the rise in the United States, ...

Eli Lilly's Ozempic-rivaling weight-loss pill orforglipron could be available in early 2026. Its retatrutide may be as ...

Shares in Novo Nordisk were up nearly 12% today – hiking its valuation to more than $280 billion – after it reported new clinical data with one of its obesity drug candidates. The new results ...

Novo Nordisk (NYSE:NVO) shares are rallying 6.87% to $86.67 as of 10:27 AM ET Friday, after the company reported promising trial results for its new obesity drug, amycretin. Warning! GuruFocus has ...

Novo Nordisk shares rose sharply Friday after the Danish pharmaceutical giant said an experimental weight-loss shot helped patients lose 22% of their body weight in a clinical trial. Shares were 7 ...

A novel GLP-1 and amylin receptor agonist featured a safety profile similar to other incretin-based therapies and conferred a ...

The biotech has named Jamie Coleman its chief commercial officer, per a Monday announcement, putting her in charge of the ...

Ozempic and Wegovy do the same thing as GLP-1 would normally do for you — but to enable them to treat diabetes and obesity, ...

Amycretin could give Novo a buzzy product in a newly competitive obesity market. It works similarly to existing GLP-1 ...